Novo Nordisk looks beyond weight loss and diabetes to expand in new illnesses

As No­vo Nordisk hauls in huge sales from its pop­u­lar GLP-1 prod­ucts, the com­pa­ny is think­ing about a fu­ture be­yond obe­si­ty and di­a­betes.

Dur­ing a press call Tues­day, No­vo ex­ec­u­tives laid out am­bi­tions in a hand­ful of con­di­tions, in­clud­ing liv­er dis­ease, chron­ic kid­ney dis­ease and Alzheimer’s. And it has the as­sets to grow — last year, it re­port­ed net prof­its of 83.7 bil­lion Dan­ish kro­ner ($12.2 bil­lion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.